Trial Profile
A Retrospective, Cohort study to evaluate the treatment adherence of OACs (warfarin, dabigatran, rivaroxaban, and apixaban) in real-world patients with nonvalvular atrial fibrillation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Sep 2018
Price :
$35
*
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Stroke
- Focus Therapeutic Use
- 24 Sep 2018 New trial record
- 26 Aug 2018 Results presented at the 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management